NAD+, often referred to as a cell's "fuel regulator," is integral to energy production, DNA repair, and overall cellular function. However, as individuals age, the levels of NAD+ naturally decline, which has been associated with cognitive decline, diminished muscle strength, and an increased susceptibility to age-related ailments.
Dr. Jianying Zhang, a leading author of a recent study, notes, "Optimizing NAD+ metabolism presents a significant opportunity to mitigate health declines associated with aging and diseases like premature aging." He emphasizes the necessity for further research to determine optimal dosages, long-term safety, and individual responses to NAD+ enhancement strategies.
Clinical Trials Show Promise for NAD+ Supplements
The review synthesizes extensive laboratory and clinical research aimed at elevating NAD+ levels. Various approaches, including the use of vitamin-like compounds such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), have shown encouraging early results, with some studies indicating enhancements in memory, mobility, and metabolic health.
Despite these positive outcomes, the researchers advocate for larger and more prolonged studies to verify the efficacy of these treatments across a broader range of conditions.
Growing Interest in NAD+ Therapies
This publication emerges amid a surge of interest from both the scientific community and the public. Ongoing clinical trials are being conducted globally, including in Norway, to evaluate the effectiveness of NAD+ precursors like NR and NMN. Concurrently, these compounds are gaining traction in the expanding global supplement market, sparking discussions about the most effective options and the applicability of animal study results to human health.
"The timing is crucial for sharing expert insights," asserts Dr. Evandro Fei Fang-Stavem, senior author and head of the Fang Lab at UiO and Ahus. "NAD+ is essential for life, yet there remains considerable confusion regarding the most effective supplements and their usage. Our article aims to consolidate evidence and provide a scientific framework to guide ongoing research and future clinical applications."
Prof. Torbjørn Omland, Deputy Head of the Institute of Clinical Medicine and co-author, highlights, "There exists a knowledge gap regarding NAD+ and its clinical implications. This review serves as a valuable resource for researchers and clinicians engaged in NAD+ studies and will inform numerous NAD+-based clinical trials targeting various conditions, including neurological and cardiovascular diseases."
Call for Enhanced Research and Collaboration
The authors stress that while NAD+-based therapies are under investigation, fostering collaboration and conducting more rigorous clinical trials are vital steps. These efforts will be essential for translating initial findings into safe and effective treatments for aging and related diseases.
Contributors from Norway include Sofie Lautrup, Hilde Loge Nilsen, and others from various esteemed institutions, including the University of Copenhagen and Harvard Medical School.